Tag: Compared

Posted on

Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Patients With Asthma

Condition:   Asthma
Interventions:   Drug: Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX;   Drug: SYMBICORT TURBOHALER budesonide and formoterol fumarate
Sponsors:   Teva Pharmaceutical Industries;   Teva Branded Pharmaceutical Products, R&D Inc.
Not yet recruiting – verified February 2014

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Posted on

A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Condition:   Pulmonary Disease, Chronic Obstructive
Interventions:   Drug: Umeclidinium bromide/Vilanterol;   Drug: Placebo ACCUHALER/DISKUS;   Drug: Fluticasone propionate/Salmeterol;   Drug: Placebo NDPI
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Not yet recruiting – verified April 2013

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Posted on

Evaluation of Tiotropium 2.5 and 5 Mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 Mcg Twice Daily) in Patient With Moderate Persistent Asthma II

Condition:   Asthma
Interventions:   Drug: 50 mcg salmeterol HFA MDI;   Drug: placebo;   Drug: 5 mcg tiotropium Respimat®;   Drug: 2.5 mcg tiotropium Respimat®
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Pfizer
Recruiting – verified September 2010

View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days

Posted on

Program to Enhance Communication of Life-sustaining Treatment Preferences Associated with Closer Adherence to a Person’s Wishes when Compared with Traditional Practices, Finds NIH-Supported Study

A program in which individuals used a standardized form signed by a physician to communicate their end-of-life care preferences on issues such as levels of medical intervention and tube feeding lead to significantly better adherence to treatment preferences than more traditional methods of communication, according to a new study.

View full post on National Institutes of Health (NIH) News Releases